FASEB SRC on HDACs, Sirtuins and Reversible Acetylation in Signaling and Disease

FASEB SRC 关于 HDAC、Sirtuins 以及信号传导和疾病中的可逆乙酰化

基本信息

批准号：
8595760
负责人：
SCOTT W HIEBERT
金额：
$ 0.7万
依托单位：
FEDERATION OF AMER SOC FOR EXPER BIOLOGY
依托单位国家：
美国
项目类别：
财政年份：
2013
资助国家：
美国
起止时间：
2013-07-15 至 2014-06-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8595760
关键词：
Acetylation Acetyltransferase Aging Aging-Related Process American Animal Disease Models Animal Model Area Basic Science Biochemistry Biological Biological Process Biology Bromodomain Cardiovascular Diseases Cell Cycle Progression Cell Differentiation process Cell physiology Cells Cellular biology Charge Chromatin Structure Clinical Clinical Investigator Clinical Research Clinical Treatment Clinical Trials Cloning Collaborations Communities Country DNA biosynthesis Data Development Diabetes Mellitus Disease Docking Drug Industry Drug Targeting Ensure Enzymes European Event Faculty Female Fertilization Fingers Fostering Future Gene Expression Gene Expression Regulation Gene Proteins Generations Genome Stability Goals HDAC1 gene HIV Infections Health Heart Hypertrophy Histones Housing Human In Vitro International Italy Knowledge Link London Longevity Lysine Malignant Neoplasms Metabolic Diseases Metabolism Methylation Modification Molecular Biology Molecular Mechanisms of Action Molecular Structure Neurodegenerative Disorders Neuromuscular Diseases Oral Participant Pathogenesis Pathology Pathway interactions Pharmaceutical Preparations Pharmacologic Substance Pharmacology Phosphorylation Physiology Play Post-Translational Protein Processing Process Protein Acetylation Proteins Reader Regulation Research Research Personnel Resveratrol Role Scientist Side Signal Transduction Sirtuins Site Solid Neoplasm Speed Stem cells Structure Testing Time Translational Research Ubiquitination Underrepresented Minority Woman abstracting base career career development drug discovery fighting graduate student human disease in vivo inhibitor/antagonist innovation interest leukemia/lymphoma meetings nervous system disorder next generation novel novel therapeutics posters preclinical study prevent programs protein function public health relevance red wine research clinical testing small molecule social sound symposium therapeutic target yeast genetics

项目摘要

DESCRIPTION (provided by applicant): Histone deacetylases (HDACs) are vital regulators of fundamental cellular events, including cell cycle progression, stem cell functions, cell fate determination, cell differentiation, and the pathogenesis of many diseases. As such, it is not surprising that protein acetylation is central to human diseases, as diverse as neurodegenerative disorders, cardiac hypertrophy, cancer, HIV infection, and more generally the process of aging. More importantly, small molecule HDAC inhibitors and activators are currently in clinical trials for the treatment of leukemia and lymphoma, solid tumors, neuromuscular disorders, metabolic disorders and other diseases. In addition, the Sirtuins, a subclass of HDACs, were fingered in yeast genetic studies as regulating lifespan, and these enzymes might be targeted by resveratrol, one of the components in red wine that has been linked to increased lifespan in humans. Therefore, a thorough understanding of HDACs is required, not merely for understanding the regulation of chromatin structure, gene regulation and protein function, but also because HDACs are intimately involved in normal and abnormal cellular processes that greatly impact human health. With the identification, isolation, cloning and functional characterization of 18 human HDACs (HDAC1- 11 and SIRT1-7) and many acetyltransferases in the past decade, the coming years will see a continued dramatic expansion in our knowledge of the biological roles of HDACs and protein acetylation. As the only conference dedicated to this field, this biannual meeting plays an essential role in bringing together approximately 44 basic and clinical scientist speakers to exchange information and develop new therapeutic avenues with approximately 120 participants from around the world. A primary objective is to transfer knowledge between basic academic researchers, clinical scientists, and pharmaceutical scientists to create efficiencies in understanding how they control human health and how these activities can be harnessed to fight a diverse slate of diseases. A second objective is to foster the development and interests of younger investigators to help support their career development. To accomplish these objectives, the meeting venue houses meeting space, dining, and rooms so that participants have ample time to move from formal presentations to informal brainstorming and collaborative discussions. In addition, the morning and evening oral presentation sessions include 2-3 talks from junior scientists selected from the submitted abstracts, which is important for career development and to encourage the next generation of HDAC scientists. There will be an emphasis through both the scientific and social programs on creating a global HDAC community. This meeting will be particularly timely because data from on a new generation of HDAC and Bromodomain drugs will be presented. Therefore, support is requested for the 4th biannual conference on the biology and therapeutic targeting of HDACs and Sirtuins, and their role in aging and disease to be held at Il Ciocco, Lucca, Italy, August 18-23, 2013 in conjunction with FASEB.

描述（由申请人提供）：组蛋白脱乙酰基酶（HDAC）是基本细胞事件的重要调节剂，包括细胞周期进展，干细胞功能，细胞命运测定，细胞分化以及许多疾病的发病机理。因此，毫不奇怪的是，蛋白质乙酰化对人类疾病的核心是至关重要的，如神经退行性疾病，心脏肥大，癌症，HIV感染以及更普遍的衰老过程。更重要的是，小分子HDAC抑制剂和激活剂目前正在接受临床试验，以治疗白血病和淋巴瘤，实体瘤，神经肌肉疾病，代谢性疾病和其他疾病。此外，Sirtuins是HDAC的一个子类，在酵母遗传研究中指定为调节寿命，这些酶可能是白藜芦醇的靶向，白藜芦醇是红葡萄酒中与人类寿命增加有关的红酒中的一种。因此，需要对HDAC进行彻底的了解，不仅是为了理解染色质结构，基因调节和蛋白质功能的调节，还因为HDAC与正常和异常的细胞过程密切相关，这极大地影响了人类健康。在过去十年中，18人HDAC（HDAC1- 11和SIRT1-7）和许多乙酰基转移酶的鉴定，隔离，克隆和功能表征，未来几年将在我们对HDAC和蛋白质乙酰化的生物学作用方面持续显着扩展。作为唯一致力于该领域的会议，这次每年一次的会议在将大约44位基本和临床科学家演讲者汇集在一起，以交换信息并开发新的治疗途径，并与来自世界各地的大约120名参与者一起开发新的治疗途径。一个主要目标是在基本的学术研究人员，临床科学家和制药科学家之间转移知识，以创造效率，以了解他们如何控制人类健康以及如何利用这些活动来抗击各种各样的疾病。第二个目标是促进年轻调查人员的发展和利益，以帮助支持他们的职业发展。为了实现这些目标，会议场所会议场所会议空间，用餐和房间，以便参与者有足够的时间从正式的演讲转变为非正式的集思广益和协作讨论。此外，早晨和晚上的口头演示会议包括来自提交摘要的初级科学家的2-3场演讲，这对于职业发展至关重要，并鼓励下一代HDAC科学家。通过创建全球HDAC社区的科学和社会计划将重点强调。这次会议将特别及时，因为将介绍来自新一代HDAC和溴化域药物的数据。因此，请求支持HDAC和Sirtuins的生物学和治疗性靶向第四次双年度会议，以及它们在2013年8月18日至23日在意大利IL Ciocco举行的衰老和疾病中的作用，2013年8月18日至23日与Paseb结合。